TY - JOUR
T1 - Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?
AU - Kendi, Ayse Tuba Karagulle
AU - Magliocca, Kelly
AU - Corey, Amanda
AU - Nickleach, Dana C.
AU - Galt, James
AU - Higgins, Kristin
AU - Beitler, Jonathan J.
AU - El-Deiry, Mark W.
AU - Wadsworth, J. Trad
AU - Hudgins, Patricia A.
AU - Saba, Nabil F.
AU - Schuster, David M.
N1 - Publisher Copyright:
© 2014 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/3/13
Y1 - 2015/3/13
N2 - OBJECTIVE: The aim of this study was to explore the relationship of PET/CT parameters with human papillomavirus (HPV) status of oropharyngeal (OP) and oral cavity (OC) squamous cell carcinomas (SCCs). PATIENTS AND METHODS: We retrospectively reviewed 39 patients with OC and OP-SCC who underwent staging F-FDG PET/CT. PET/CT parameters were measured for the primary tumor and the hottest involved node, including SUVmax, SUVmean, SUVpeak, metabolic tumor volume, total lesion glycolysis, standardized added metabolic activity (SAM), and normalized SAM. Patient characteristics were compared between HPV positive (HPV+) and negative (HPV-) groups. Receiver operating characteristic analysis was used to dichotomize PET/CT parameters into high and low. Logistic regression models predicting HPV status were fit for each PET/CT parameter. RESULTS: The HPV+ group was composed of 18 patients all with OP-SCC; the HPV- group consisted of 21 patients, 4 OP cancer patients and 17 OC cancer patients. The HPV+ group had a higher proportion of N2 stage (94% vs 43%; P < 0.001). Nodal PET/CT parameters were higher in the HPV+ group (P < 0.01); this difference was not present for the primary lesion. After adjusting for sex and age, the association of higher nodal SUVmax (odds ratio [OR], 9.67), SUVmean (OR, 10.48), SUVpeak (OR 9.67), metabolic tumor volume (OR, 14.52), total lesion glycolysis (OR, 11.84), and SAM, normalized SAM (OR, 16.21) with HPV+ status remained statistically significant (P < 0.05). CONCLUSIONS: Nodal PET/CT parameters predict HPV status. High nodal FDG uptake should raise suspicion for positive HPV status in the evaluation of the primary lesion.
AB - OBJECTIVE: The aim of this study was to explore the relationship of PET/CT parameters with human papillomavirus (HPV) status of oropharyngeal (OP) and oral cavity (OC) squamous cell carcinomas (SCCs). PATIENTS AND METHODS: We retrospectively reviewed 39 patients with OC and OP-SCC who underwent staging F-FDG PET/CT. PET/CT parameters were measured for the primary tumor and the hottest involved node, including SUVmax, SUVmean, SUVpeak, metabolic tumor volume, total lesion glycolysis, standardized added metabolic activity (SAM), and normalized SAM. Patient characteristics were compared between HPV positive (HPV+) and negative (HPV-) groups. Receiver operating characteristic analysis was used to dichotomize PET/CT parameters into high and low. Logistic regression models predicting HPV status were fit for each PET/CT parameter. RESULTS: The HPV+ group was composed of 18 patients all with OP-SCC; the HPV- group consisted of 21 patients, 4 OP cancer patients and 17 OC cancer patients. The HPV+ group had a higher proportion of N2 stage (94% vs 43%; P < 0.001). Nodal PET/CT parameters were higher in the HPV+ group (P < 0.01); this difference was not present for the primary lesion. After adjusting for sex and age, the association of higher nodal SUVmax (odds ratio [OR], 9.67), SUVmean (OR, 10.48), SUVpeak (OR 9.67), metabolic tumor volume (OR, 14.52), total lesion glycolysis (OR, 11.84), and SAM, normalized SAM (OR, 16.21) with HPV+ status remained statistically significant (P < 0.05). CONCLUSIONS: Nodal PET/CT parameters predict HPV status. High nodal FDG uptake should raise suspicion for positive HPV status in the evaluation of the primary lesion.
KW - F-FDG
KW - PET
KW - head and neck carcinoma
KW - human papillomavirus
UR - http://www.scopus.com/inward/record.url?scp=84922670894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922670894&partnerID=8YFLogxK
U2 - 10.1097/RLU.0000000000000691
DO - 10.1097/RLU.0000000000000691
M3 - Article
C2 - 25608156
AN - SCOPUS:84922670894
SN - 0363-9762
VL - 40
SP - e196-e200
JO - Clinical nuclear medicine
JF - Clinical nuclear medicine
IS - 3
ER -